You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Adjuvant Taxane Therapy for Women with Early-stage, Invasive Breast Cancer

Version: 2 ID: 1-7 Sep 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Breast Cancer Disease Site Group

Research Question(s)

  1. Compared with a standard anthracycline-based regimen (e.g., doxorubicin and cyclophosphamide [AC], 5-fluorouracil, doxorubicin, and cyclophosphamide [FAC], 5- fluorouracil, epirubicin, and cyclophosphamide [500/100/500mg/m2 ] [FEC-100], or cyclophosphamide, epirubicin, 5-fluorouracil [75/60/100mg/m2 ] [CEF]), does a concurrent taxane-anthracycline regimen improve clinically meaningful outcomes (disease-free and overall survival)?
  2. Compared with an anthracycline-based regimen, does a sequential taxane–anthracycline regimen improve clinically meaningful outcomes?
  3. Compared with a standard (three-weekly) anthracycline–taxane regimen, does a dosedense (two-weekly) regimen improve clinically meaningful outcomes?
  4. Compared with an anthracycline-based regimen, does a non-anthracycline taxane regimen improve clinically meaningful outcomes?
  5. What are the harms associated with adjuvant taxane regimens? Target Population Women with T 1-3, operable, node-positive breast cancer.
pdf download Summary (PDF) (189.47 KB)